AIM ImmunoTech reported positive stockholders' equity of $7.7 million as of June 30. This was included in its second-quarter 2026 report. The company previously recorded a $9.8 million deficit at the end of 2025. Equity offerings and warrant exercises generated $14.4 million in net cash during the first half of the year. These actions drove the improvement.
The company regained compliance with the NYSE American's minimum stockholders' equity requirement of $6.0 million. Operating performance, however, remains a challenge. The company reported Q2 revenue of $26,000. It also posted a net loss of $3.8 million.
Management stated that recurring losses and significant operating cash outflows raise substantial doubt about the company's ability to continue as a going concern for at least the next year. Cash and equivalents totaled $9.9 million at the end of the quarter.